Tonix Pharmaceuticals Holding Corp. [NASDAQ: TNXP] closed the trading session at $0.66 on 07/08/20. The day’s price range saw the stock hit a low of $0.615, while the highest price level was $0.6899. On July 7, Tonix announced that it is set to purchase a facility in Massachusetts based on almost 40,000 sq foot area. The company plans to utilize this new center as its R&D laboratory to work on its ongoing COVID-19 vaccine including other major biological disorder projects.
This new development center will be Tonix’s most equipped center that will improve its abilities in biological development and analytical progress. With most of the biological firms working on finding the potential cure for COVID-19, Tonix expects to work swiftly with control over its research on vaccines and other biological products, especially the ongoing work on coronavirus vaccine.
The stocks have a year to date performance of -43.59 percent and weekly performance of 8.11 percent. The stock has been moved at -59.51 percent over the last six months. The stock has performed -9.22 percent around the most recent 30 days and changed -5.85 percent over the most recent 3-months.
If compared to the average trading volume of 7.81M shares, TNXP reached to a volume of 30117177 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Tonix Pharmaceuticals Holding Corp. [TNXP]:
ROTH Capital have made an estimate for Tonix Pharmaceuticals Holding Corp. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on April 18, 2019. The new note on the price target was released on August 18, 2017, representing the official price target for Tonix Pharmaceuticals Holding Corp. stock. On February 17, 2016, analysts decreased their price target for TNXP shares from 18 to 10.
The Average True Range (ATR) for Tonix Pharmaceuticals Holding Corp. is set at 0.05 The Price to Book ratio for the last quarter was 0.51, with the Price to Cash per share for the same quarter was set at 0.58.
TNXP stock trade performance evaluation
Tonix Pharmaceuticals Holding Corp. [TNXP] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 8.11. With this latest performance, TNXP shares dropped by -9.22% in over the last four-week period, additionally sinking by -59.51% over the last 6 months – not to mention a drop of -94.16% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TNXP stock in for the last two-week period is set at 55.85, with the RSI for the last a single of trading hit 63.68, and the three-weeks RSI is set at 51.20 for Tonix Pharmaceuticals Holding Corp. [TNXP]. The present Moving Average for the last 50 days of trading for this stock 0.6642, while it was recorded at 0.6130 for the last single week of trading, and 1.4751 for the last 200 days.
Tonix Pharmaceuticals Holding Corp. [TNXP]: An insightful look at the core fundamentals
Return on Total Capital for TNXP is now -172.42, given the latest momentum, and Return on Invested Capital for the company is -172.99. Return on Equity for this stock declined to -173.02, with Return on Assets sitting at -140.02. When it comes to the capital structure of this company, Tonix Pharmaceuticals Holding Corp. [TNXP] has a Total Debt to Total Equity ratio set at 3.80. Additionally, TNXP Total Debt to Total Capital is recorded at 3.66, with Total Debt to Total Assets ending up at 2.46. Long-Term Debt to Equity for the company is recorded at 0.06, with the Long-Term Debt to Total Capital now at 0.06.
Reflecting on the efficiency of the workforce at the company, Tonix Pharmaceuticals Holding Corp. [TNXP] managed to generate an average of -$1,788,625 per employee.Tonix Pharmaceuticals Holding Corp.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 12.60 and a Current Ratio set at 12.60.
Earnings per share (EPS) analysis for Tonix Pharmaceuticals Holding Corp. [TNXP] stock
With the latest financial reports released by the company, Tonix Pharmaceuticals Holding Corp. posted -9.5/share EPS, while the average EPS was predicted by analysts to be reported at -9.87/share.When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 3.70%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TNXP.
Tonix Pharmaceuticals Holding Corp. [TNXP]: Insider Ownership positions
There are presently around $1 million, or 7.70% of TNXP stock, in the hands of institutional investors. The top three institutional holders of TNXP stocks are: VANGUARD GROUP INC with ownership of 383,084, which is approximately New of the company’s market cap and around 0.06% of the total institutional ownership; RENAISSANCE TECHNOLOGIES LLC, holding 305,532 shares of the stock with an approximate value of $0.18 million in TNXP stocks shares; and GEODE CAPITAL MANAGEMENT, LLC, currently with $51000.0 in TNXP stock with ownership of nearly New of the company’s market capitalization.
Positions in Tonix Pharmaceuticals Holding Corp. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 12 institutional holders increased their position in Tonix Pharmaceuticals Holding Corp. [NASDAQ:TNXP] by around 644,157 shares. Additionally, 3 investors decreased positions by around 54,150 shares, while 6 investors held positions by with 251,571 shares. The mentioned changes placed institutional holdings at 949,878 shares, according to the latest SEC report filing. TNXP stock had 11 new institutional investments in for a total of 644,156 shares, while 1 institutional investors sold positions of 39,456 shares during the same period.